Bristol-Myers Squibb

BMY · NYSE

$61.68+$2.85 (+4.84%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $58.83

BMY analyst rating

HoldConsensus of 18 analysts over the last 12 months. 44% rate it a buy.

Strong buy0
Buy8
Hold9
Underperform1
Sell0

12-month price target · 27 analysts

Average $68.14 (+10.5% upside)

Low: $40.40
Now: $61.68
High: $86.10

Upgrades and downgrades

The latest rating actions, newest first

BMY analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Wells Fargo	Oct 13, 2026	Maintains	Equal-Weight	$65.00 → $60.00	68%
Cantor Fitzgerald	Oct 8, 2026	Maintains	Neutral	$59.00 → $53.00	64%
Morgan Stanley	Oct 7, 2026	Maintains	Underweight	$40.00 → $41.00	63%
Leerink Partners	Oct 5, 2026	Downgrade	Outperform → Market Perform	$73.00 → $59.00	71%
Piper Sandler	Sep 16, 2026	Maintains	Overweight	$75.00 → $82.00	68%
HSBC	Sep 10, 2026	Maintains	Hold	$60.00 → $65.00	59%
Argus Research	Aug 5, 2026	Upgrade	Hold → Buy	$75.00	51%
Citigroup	Aug 3, 2026	Maintains	Neutral	$66.00 → $70.00	60%
RBC Capital	Jul 31, 2026	Maintains	Sector Perform	$60.00 → $64.00	73%
JP Morgan	Jul 31, 2026	Maintains	Overweight	$67.00 → $73.00	65%

The case for and against

Updated Sep 25, 2026

Bull case

Bristol-Myers Squibb is expected to have a strong quarter driven by growth products such as Opdivo and Qvantig, as well as continued growth in Eliquis. The team is confident in the company's 10-15% growth target for Eliquis for the year, with a focus on cost considerations. With upcoming clinical readouts and potential label expansions, Bristol-Myers Squibb has the opportunity for multiple expansion and is a buy according to analysts, with a target price of $72.

Bear case

Bristol-Myers Squibb is facing downside risks due to potential competition in its key therapeutic areas, clinical failures in their pipeline, and potential regulatory delays. With 70% of total sales coming from the US, the company is highly exposed to any changes in the US market, posing additional macro/policy-related risks. Despite its strong position in the immuno-oncology market, these risks could lead to a negative outlook on the company's stock.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.